Angers Stephane, Salahpour Ali, Bouvier Michel
Department of Biochemistry and Groupe de Recherche sur le Système Nerveux Autonome, Université de Montréal, Montréal, H3C 3J7, Canada.
Annu Rev Pharmacol Toxicol. 2002;42:409-35. doi: 10.1146/annurev.pharmtox.42.091701.082314.
In the last four to five years, the view that G protein-coupled receptors (GPCRs) function as monomeric proteins has been challenged by numerous studies, which suggests that GPCRs exist as dimers or even higher-structure oligomers. Recently, biophysical methods based on luminescence and fluorescence energy transfer have confirmed the existence of such oligomeric complexes in living cells. Although no consensus exists on the role of receptor dimerization, converging evidence suggests potential roles in various aspects of receptor biogenesis and function. In several cases, receptors appear to fold as constitutive dimers early after biosynthesis, whereas ligand-promoted dimerization at the cell surface has been proposed for others. The reports of heterodimerization between receptor subtypes suggest a potential level of receptor complexity that could account for previously unexpected pharmacological diversities. In addition to fundamentally changing our views on the structure and activation processes of GPCRs, the concept of homo- and heterodimerization could have dramatic impacts on drug development and screening.
在过去的四到五年里,认为G蛋白偶联受体(GPCRs)作为单体蛋白发挥作用的观点受到了众多研究的挑战,这些研究表明GPCRs以二聚体甚至更高结构的寡聚体形式存在。最近,基于发光和荧光能量转移的生物物理方法证实了活细胞中存在此类寡聚复合物。尽管对于受体二聚化的作用尚无定论,但越来越多的证据表明其在受体生物发生和功能的各个方面都具有潜在作用。在一些情况下,受体似乎在生物合成后早期就折叠成组成型二聚体,而对于其他受体则有人提出在细胞表面存在配体促进的二聚化。受体亚型之间异源二聚化的报道表明了受体复杂性的一个潜在层面,这可能解释了先前意外的药理学多样性。除了从根本上改变我们对GPCRs结构和激活过程的看法外,同型和异型二聚化的概念可能会对药物开发和筛选产生巨大影响。